Search 

Mitochondria play a central role in metabolic diseases and cancer. Targeting mitochondria for therapeutic development provides a unique opportunity for the effective treatment of these devastating diseases, including nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and various cancers.

Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.

We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.

MSA manages over $1.5 billion and invests in global leading early and growth-stage technology-enabled companies.

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.

Cardiac Focused Stem Cell /Secretome Exosome company . Immortalized cell line

关注科技驱动的商业创新，TMT、大健康、生物技术

Next Pharma Inc. (NPI) is a biotechnology company headquartered in Toronto, Canada, focused on developing and commercializing products for early detection, diagnosis, and monitoring of the recurrence of Cancer and COVID-19 disease.
NPI is headquartered in Toronto, Ontario, Canada and will globally distribute and commercialize its AABH based diagnostic tests. NPI’s diagnostic tests are regarded as revolutionary as they can help to diagnose cancer at an early stage using a blood serum with high sensitivity/high specificity, fast turnaround (within 7 hours), are relatively inexpensive and are non-invasive.

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides Looking for services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/Licensing-out of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.

OP Financial Limited (1140.HK) is a cross-border and cross-sector investment company that listed on the main board of the Stock Exchange of Hong Kong Limited. OP Financial has strong capability of investment, financing and industry consolidation, while its investment portfolios cover many listed and unlisted company across geographies and industries. According to the investment cycle, OP Financial builds cross-cycle portfolios with long-term core holding companies, medium-term private equity and venture capital funds and short-term arbitrage project, which are tailored to create steady returns for the shareholders.

VC focused on healthcare industry